KR20240125970A - EGFR-cMET-표적화 화합물 및 이의 용도 - Google Patents

EGFR-cMET-표적화 화합물 및 이의 용도 Download PDF

Info

Publication number
KR20240125970A
KR20240125970A KR1020247024103A KR20247024103A KR20240125970A KR 20240125970 A KR20240125970 A KR 20240125970A KR 1020247024103 A KR1020247024103 A KR 1020247024103A KR 20247024103 A KR20247024103 A KR 20247024103A KR 20240125970 A KR20240125970 A KR 20240125970A
Authority
KR
South Korea
Prior art keywords
amino acid
acid sequence
sequence
region
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247024103A
Other languages
English (en)
Korean (ko)
Inventor
사다프 아그헤브리안
나탈리 그린슈타인
이언 알. 더피
토마스 아이. 코스텔닉
앤드류 그리어 뷰캐넌
야리브 마조
스리나스 카스투리랑간
쿤 두
처닝 양
프랭크 어바인 커머
Original Assignee
퓨전 파마슈티칼즈 인크.
아스트라제네카 유케이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 퓨전 파마슈티칼즈 인크., 아스트라제네카 유케이 리미티드 filed Critical 퓨전 파마슈티칼즈 인크.
Publication of KR20240125970A publication Critical patent/KR20240125970A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247024103A 2021-12-20 2022-12-20 EGFR-cMET-표적화 화합물 및 이의 용도 Pending KR20240125970A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163291910P 2021-12-20 2021-12-20
US63/291,910 2021-12-20
PCT/US2022/082021 WO2023122588A2 (en) 2021-12-20 2022-12-20 Egfr-cmet–targeted compounds and uses thereof

Publications (1)

Publication Number Publication Date
KR20240125970A true KR20240125970A (ko) 2024-08-20

Family

ID=86903719

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247024103A Pending KR20240125970A (ko) 2021-12-20 2022-12-20 EGFR-cMET-표적화 화합물 및 이의 용도

Country Status (15)

Country Link
US (1) US20250121104A1 (enExample)
EP (1) EP4452954A2 (enExample)
JP (1) JP2025500944A (enExample)
KR (1) KR20240125970A (enExample)
CN (1) CN118765273A (enExample)
AR (1) AR128052A1 (enExample)
AU (1) AU2022419564A1 (enExample)
CA (1) CA3244030A1 (enExample)
CL (1) CL2024001832A1 (enExample)
CO (1) CO2024008733A2 (enExample)
CR (1) CR20240254A (enExample)
IL (1) IL313333A (enExample)
MX (1) MX2024007596A (enExample)
TW (1) TW202333799A (enExample)
WO (1) WO2023122588A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3265502A1 (en) * 2022-08-22 2024-02-29 Abdera Therapeutics Inc. DOTA ANTIBODY CONJUGATES VHH
EP4763865A1 (en) * 2023-08-14 2026-06-24 Minghui Pharmaceutical (Hangzhou) Limited Anti-c-met nanobody and use thereof
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技（上海）有限公司 一种抗体偶联药物及其用途
CN118085101A (zh) * 2024-03-01 2024-05-28 烟台蓝纳成生物技术有限公司 一种二价双特异性抗体、抗体偶联核素药物及其应用
WO2025195500A1 (zh) * 2024-03-22 2025-09-25 康源博创生物科技(北京)有限公司 一种多肽及其用于构建包含共同轻链的双特异性抗体中的应用
WO2026149557A1 (zh) * 2025-01-10 2026-07-16 正大天晴药业集团股份有限公司 新型亲水性连接体及其药物连接体、蛋白质偶联药物、药物组合物和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3823988A1 (en) * 2018-07-19 2021-05-26 Eli Lilly and Company Bispecific antibodies targeting immune checkpoints
WO2021133036A1 (ko) * 2019-12-23 2021-07-01 주식회사 엘지화학 항-lilrb1 항체 및 그의 용도
KR20220157464A (ko) * 2020-03-23 2022-11-29 퓨전 파마슈티칼즈 인크. Fgfr3-표적화된 방사선면역접합체 및 그의 용도
WO2021207086A1 (en) * 2020-04-06 2021-10-14 Fusion Pharmaceuticals Inc. Tem-1-targeted radioimmunoconjugates and uses thereof

Also Published As

Publication number Publication date
CA3244030A1 (en) 2023-06-29
CN118765273A (zh) 2024-10-11
MX2024007596A (es) 2024-07-09
US20250121104A1 (en) 2025-04-17
TW202333799A (zh) 2023-09-01
CL2024001832A1 (es) 2024-11-22
JP2025500944A (ja) 2025-01-15
EP4452954A2 (en) 2024-10-30
AR128052A1 (es) 2024-03-20
AU2022419564A1 (en) 2024-07-04
WO2023122588A3 (en) 2023-09-21
IL313333A (en) 2024-08-01
CO2024008733A2 (es) 2024-07-29
CR20240254A (es) 2025-01-13
WO2023122588A2 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
US20250121104A1 (en) Egfr-cmet-targeted compounds and uses thereof
KR20250071294A (ko) Dll3 결합 분자 및 이의 용도
EP4423137A1 (en) Claudin 18.2-targeted compounds and uses thereof
TW202304532A (zh) 治療癌症之方法
WO2021207086A1 (en) Tem-1-targeted radioimmunoconjugates and uses thereof
KR20240099208A (ko) EGFRvIII-표적화 화합물 및 그의 용도
JP2023518818A (ja) Ｆｇｆｒ３に標的化されたラジオイムノコンジュゲートおよびその使用
US20240350682A1 (en) Steap2-targeted compounds and use thereof
WO2024216389A9 (en) Claudin 18.2-targeted compounds and uses thereof
TW202600607A (zh) Ｄｄｌ３結合免疫接合物及其用途
TW202508645A (zh) 放射性藥物用於癌症治療之用途
HK40084697A (en) Fgfr3-targeted radioimmunoconjugates and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000